NantHealth Names Wise to Its Board of Directors
18 March 2020 - - US-based personalised healthcare company NantHealth, Inc. (NASDAQ: NH) has appointed Deanna L. Wise, senior vice president and chief information officer for Banner Health, to NantHealth's board of directors, the company said.

Wise brings more than 25 years of experience in the development and maintenance of leading clinical IT systems in the hospital and health care industry.

Wise joined Banner Health in 2019 and has focused on developing an innovative and inviting healthcare consumer and clinician experience.

Prior to joining Banner Health, Wise served as the chief information officer at Dignity Health where she played a key role in Dignity Health's Horizon 2020 goal of competing in a reformed health care system that includes industry-leading clinical IT.

She oversaw the implementation of Dignity Health's Electronic Health Record software standard to provide electronic records to each Dignity Health facility.

Wise also facilitated the creation of a state-of-the-art clinically integrated predicative analytics program.

Wise also served as the chief information officer for Vanguard Health Systems and Vanguard's Abrazo Health Care Phoenix market where she succeeded in developing a staff that steadily improved customer satisfaction while increasing the retention and satisfaction scores of the IT team.

Additionally, Wise held leadership roles at Maricopa County Health District and St. Vincent Hospital.

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organisations.

NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes.

Its comprehensive product portfolio combines the latest technology in payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA and RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer).